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Background
Platelet-collagen interactions are believed to be of great significance in physiological 
hemostasis and pathological thrombosis [1]. During this process, binding of immuno-
globulin (Ig)-like receptor glycoprotein VI (GPVI) to collagen is recognized as a central 
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step [2], which leads to platelet integrin α2β1 activation and platelet granule release [3, 4]. 
Activated α2β1 could bind tightly to collagen and mediate firm adhesion of platelets to the 
injury site [5], while platelet granule contents would activate nearby circulating platelets 
and propagate thrombus formation. Therefore, GPVI becomes a primary therapeutic tar-
get for prevention of arterial thrombotic diseases such as heart attack and stroke [6].
Anti-GPVI antibody 10B12 is a potent antithrombotic agent and receives wide atten-
tion owing to the specific and efficient blocking of GPVI-collagen interaction [7, 8]. 
Injection of single-chain antibody fragment (scFv) 10B12 abolished binding of human 
platelets to human type III collagen and collagen-related peptide (CRP) [7, 8]. Mutagen-
esis experiments have been carried out to identify the epitope residues of GPVI interact-
ing with 10B12 (Table 1). Smethurst et al. [7] found K59E substitution reduced binding 
of GPVI to CRP and 10B12, while ARG60, PHE91, ARG117, TYR118, PHE120, ARG139, 
SER164 and ARG166 were dispensable for the binding. O’connor et  al. [9] proved that 
the mutation of the residue LYS41 to alanine abolished 10B12 binding while mutation 
of ARG166 had no significant effect. The messages for paratope on 10B12 and epitope 
on GPVI is not enough so that mapping paratope to epitope is required in increasing 
the efficacy of 10B12 [10, 11]. Traditional methods, including mutagenesis, phage dis-
play peptide libraries, X-ray crystallization and nuclear magnetic resonance, are usually 
expensive, time-consuming and blind [12]. Thus, computational methods such as rigid-
body and flexible docking program are more and more used in paratope and epitope 
mapping [11, 13, 14]. Protein–protein interfaces, different from small molecules binding 
sites, are relatively large and discontinuous, leading to barriers in docking. And, pro-
tein flexibility also plays a great role in predicting druggable binding sites as well as the 
locations of interacting interfaces [11, 14–20]. The conformation transforming is missed 
completely in rigid body docking or partly in flexible docking, making it incapable to 
illustrate whether these residues are crucial or not for binding [12].
Recently, a novel computational procedure to predict paratope residues and their 
partners via molecular dynamics (MD) simulations was developed and succeeded in 
mapping paratope to epitope of 6B4/GPIbα complex [21]. Along the pathway in the 
computer strategy described in our previous work [21], the 10B12/GPVI complex model 
was constructed through homology modeling and rigid-body docking, and MD simula-
tion was used to detected the paratope residues on 10B12 and their partners on GPVI, 
with hypothesis that the dominant linkers between paratope and epitope are mainly 
contributed by the stable hydrogen bonds and salt bridges across the complex interface. 
Twelve key and seven dispensable residues in interaction of 10B12 to GPVI were pre-
dicted, in better agreement with previous mutation experiments. The results illustrated 
that the present computer strategy might be effective in mapping paratope to epitope 
on GPVI/10B12, and have a wide application in guiding mutagenesis experiments and 
computer-aided antibody design.
Table 1 Identified interaction residues between  GPVI with  10B12 from  mutagenesis 
experiments
Function Name
Epitope residues on GPVI LYS59, LYS41 [7, 9]
Dispensable residues on GPVI ARG60, PHE91, ARG117, TYR118, PHE120, ARG139, SER164, ARG166 [7, 9]
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Methods
Homology modeling
The structure of antibody 10B12 consists of a light chain (VL and CL domains), a heavy 
chain (VH and CH domains), and a 15-amino-acid (Gly4Ser)3 linker. The amino acid 
sequence of 10B12 was obtained from NCBI (Accession: AAN15184 and AAN15185). 
The structural templates of 10B12 were built up via PDB database search with BLAST 
for homology modeling [22]. The templates for heavy-, light-chains and (Gly4Ser)3 linker 
were the crystal structures of 8F9-Fab (PDB code 3F12, 83% identity), D5-Fab (PDB 
code 2CMR, 100% identity) and Fv antibody fragment (PDB code 1F3R, 100% identity), 
respectively. To yield the most likely VH–VL orientations, the crystal structure of anti-
SARS ScFv antibody 80R (PDB code 2GHW) was used as a global template because it 
has the highest sequence identity (60%) with 10B12-ScFv among all antibody crystal 
structures containing the (Gly4Ser)3 linker in PDB based on the BLAST result. Mean-
while, both the light- and heavy-chain sequences of 10B12 were submitted to NCBI 
IgBlast (http://www.ncbi.nlm.nih.gov/igblast/) to identify complementarity determin-
ing regions (CDRs) of 10B12. CDR H1, H2, H3 in the heavy chain were made up of the 
sequences from 26th to 33rd residue, from 51st to 58th residue and from 96th to 112nd 
residue, whereas the sequences from 163rd to 168th residue, from 186th to 188th res-
idue and from 225th to 233rd residue contributed to the CDR L1, L2 and L3 in light 
chain, respectively. 10B12 was first aligned to its templates by ClustalX [23], then the 
homology modeling was performed by Modeller 9v6 [24]. Eight 10B12 models of single 
chain Fv (ScFv) were built up and the model with a smallest Z-score value was regarded 
as a native-like model and selected for further docking to GPVI.
Docking
The structure of unliganded GPVI (PDB code 2G17) was downloaded from PDB data-
base. Docking of 10B12 to GPVI was performed with ZDOCK3.0 [25] and the shallow 
groove adjacent to the C’E loop of GPVI was designated as the binding site of 10B12 
CDRs, as indicated in previous works [4]. In docking to a fixed 10B12, GPVI was trans-
lated and/or rotated with 6° sampling density in rotational space. Altogether 54,000 
poses were generated with rigid-body docking and they were then analyzed and scored 
by Zrank [26]. Top 20 complexes ranking with negative Z-rank score were taken for vis-
ual inspection with the software visual molecular dynamics (VMD) [27]. The complex 
with the lowest Z-rank score was regarded as the best model [26], which was used in 
MD simulations.
Free and steered MD simulations
Two software packages, VMD for visualization and modeling [27] and NAMD 2.9 pro-
gram for MD simulations [28], were used here. The best 10B12/GPVI complex gener-
ated by ZDOCK was solvated with TIP3P water molecules in a rectangular box of 
67.41 Å × 40.47 Å × 36.46 Å. Then Na+ and Cl− ions were added to neutralize the sys-
tems at a 150 mM salt concentration. The CHARMM22 all-atom force field [29], along 
with cMAP correction for backbone, particle mesh Ewald algorithm for electrostatic 
interaction and a 12 Å cutoff for electrostatic and van der Waals interaction, were used 
to perform MD simulations with a periodical boundary condition and a time step of 2 fs.
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First, the system was energy-minimized for 15,000 steps with all protein atoms fixed 
and for another 15,000 steps with all atoms free. Then the system was equilibrated for 
60 ns twice with pressure and temperature control. The temperature was held at 310 K 
using Langevin dynamics, and the pressure was held at one atmosphere by the Langevin 
piston method. Time-curves of the temperature, total energy and root mean square 
deviation (RMSD) of heavy atoms were used to observe whether the system had been 
equilibrated. Two equilibrated complex structures were obtained from two correspond-
ing equilibrated systems described above, and taken as the two initial conformations for 
free and steered MD simulations.
Free and steered MD simulations were run thrice on each equilibrated complex struc-
ture, respectively. Free MD simulation was conducted over 10  ns without control of 
temperature and pressure. In steered MD simulations, the C-terminal Cα atoms of both 
heavy and light chains of 10B12 were fixed and the C-terminal Cα atom of GPVI was 
steered with a virtual spring at a spring constant of 7000 pN/nm. A pulling over 9 ns was 
performed with time step 2 fs and a constant velocity of 1 nm/ns along the direction ver-
tical to the line between two fixed C-terminal Cα atoms of 10B12.
All simulations were supported by National Supercomputer Center in Guangzhou.
Survival ratio, normalized rupture time and stabilization index of a hydrogen bond
It was assumed that the interaction of a paratope residue to its partner can be scored 
out by the best stable one of H-bonds and/or salt bridges between this residue pair [21, 
30]. A hydrogen bond was defined if the donor–acceptor distance and bonding angle 
were small than 3.5 Å and 30° respectively. But only the bond-length cutoff of 3.5 Å was 
applied to examine the salt bridges in binding site. The H-bonds and/or salt bridges 
across interface of complex were detected through VMD. Survival ratio of a H-bond (or 
salt bridge) was defined as the bond survival time in the period of simulation.
The survival ratio of the jth bond (ωj) expressed its thermal stability in free MD simu-
lations. ωj = max{ωj1, ωj2}, where ωji (i = 1, 2) is the mean survival ratio of the jth bond 
detected from thrice free MD simulations with the ith initial equilibrated complex con-
formation. The normalized rupture time αj expressed the relative mechanical strength of 
the jth H-bond in steered MD simulations. αj = θj/max{θ1, θ2,…, θN}, and θj = max{θj1, 
θj2}, where N is the total number of involved H-bonds, θji is the mean rupture time of the 
jth bond detected from thrice steered MD simulations with the ith initial equilibrated 
complex conformation for i = 1, 2.
The stabilization index of the jth H-bond (HBSIj), which synthesizes the effects of both 
thermal stabilization and mechanical strength of the bond on the paratope–epitope 
interactions, was defined as that HBSIj = (ωj + αj)/2. We defined that a bond is low, mod-
erate and high stable, if anyone of its survival ratio, normalized rupture time and HBSI 
index lies in the region from 0 to 0.3, from 0.3 to 0.55 and from 0.55 to 1.0, respectively.
Results
The best docking model provided less information of epitope and paratope residues 
of 10B12/GPVI
We obtained a model of 10B12-ScFv through homology modeling (see “Methods” sec-
tion). Its six CDRs, which located on the top of both light- and heavy-chains, mainly 
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contribute to binding of 10B12 to GPVI (Fig. 1a). After that, 54,000 poses were gener-
ated by rigid-body docking of the above 10B12-ScFv to ligand-free GPVI (see “Meth-
ods” section). The 2718th complex (Fig. 1b) with the lowest Z-rank score of −106.48 was 
picked out. This complex model may be the best one, because the lowest Z-rank score 
means its conformation is most energy favorable.
Subsequent conformational analysis with VMD revealed that the selected 10B12/
GPVI model might be meaningful biologically. Katsunori Horii et al. [4, 9] found that a 
shallow groove formed by basic residues on the surface of D1 domain surface including 
LYS41, LYS59, ARG60 and ARG166, adjacent to the C’E loop, was the main binding site on 
GPVI to collagen. From Fig. 1b, we could clearly see that this region (blue) was mostly 
occupied by CDR H3 of 10B12 (purple), suggesting a competitive binding of 10B12 and 
collagen to GPVI.
Furthermore, we analyzed the H-bonds and salt bridges at the interface of the 2718th 
complex with VMD to get the information about epitope and paratope residues [21, 30]. 
Mutation data demonstrated that both LYS59 and LYS41 were key residues (Table 1) [7, 
9]. We found from 2718th complex that there existed three H-bonds and one salt bridge, 
involving four residues (GLU21, TYR47, GLN50 and LYS59) on GPVI and four residues 
(GLU1, GLY26, ASP107 and LYS186) on 10B12 (Table 2). From these eight residues, just 
LYS59 emerged and LYS41 did not. It means that, docking analysis of one static complex 
only provided less information on intermolecular interaction at binding site even if this 
conformation is energy favorable, as shown in our previous research [21]. The reason 
might be that the molecular recognition and drug binding are dynamic processes [31] 
and 10B12/GPVI complex in water should undergo a random conformational transition.
Fig. 1 The best docking model of 10B12 in binding without or with GPVI. a The best model of 10B12 from 
Homology modeling, including the light chain (cyan), heavy chain (gray), linker (yellow) and the six CDR 
regions (purple). b Conformation of 10B12 (left) bound to GPVI (right, orange). The binding sites (blue) on GPVI 
to 10B12 were shown here
Table 2 Residue interactions between 10B12 and GPVI from docking model
No. Hydrogen bond Salt bridge
GPVI 10B12 GPVI 10B12
1 GLN50 GLU1 GLU21 LYS186
2 TYR47 GLY26
3 LYS59 ASP107
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Thermal stabilization of H‑bonds marked paratope and epitope residues of 10B12/GPVI 
complex
It was demonstrated that paratopes and epitopes could be mapped by H-bonds with 
higher thermal stabilization in free MD simulations [21]. Here, the 2718th complex, 
the best model of 10B12/GPVI, was chosen to perform MD simulations. System equi-
librium was performed twice along a same protocol of energy minimization. From the 
time-curves of the temperature, total energy and RMSD of heavy atoms (Fig. 2), it was 
shown that the two systems were equilibrated after 30 ns. We examined the events of 
breaking and forming of bonds by performing free MD simulations thrice on each of ini-
tial equilibrated conformation I and II of 10B12/GPVI complex for 10 ns. Survival ratios 
of all detected H-bonds were listed in Table 3, which indicated that, in comparison with 
docking results (Table  2), two H-bonds and one salt bridge were lost but 24 H-bonds 
were newly detected. Of these detected bonding, the 2nd bond only appeared in the 
simulations for the equilibrated conformation I while the 5th–8th bonds only emerged 
from the simulations for the equilibrated conformation II (Table 3). The characteristic of 
initial state-dependent H-bonds formation suggests that a number of simulations in par-
allel are required to better understand the residue interactions across protein interface 
[21].
The maximum value of mean survival ratios with initial equilibrated conformation 
I and II was taken as the mean survival ratio (ω) of a H-bond (see “Methods” section, 
Table  3). Twenty-five H-bonds were clustered into three groups of low, moderate and 
high thermal stabilization by their corresponding mean survival ratio values ranging 
from 0 to 0.3, from 0.3 to 0.55 and from 0.55 to 1.0, respectively. The H-bonds with mod-
erate and high thermal stabilization were used to map paratope to epitope residues for 
preventing loss of potential key residues. Involved in 16 H-bonds from the 1st to the 
Fig. 2 Variation of the temperature, total energy and RMSD of heavy atoms of GPVI/10B12 complex versus 
simulation time. a, b Denote two independent system equilibrium processes (a, b) of GPVI/10B12 complex, 
respectively. Each system equilibrium process was demonstrated by the time-courses of the temperature, 
total energy and RMSD of heavy atoms of the complex
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16th bonds in Table 3), 13 residues, including ARG38, LYS41, SER44, ARG46, TYR47, LYS59 
and ARG166 on GPVI as well as GLU1, ASP98, GLU102, ASP107, ASP108 and ASP111 on 
10B12 (Fig. 3), were sorted out with a cutoff of 0.3. As expected, the key residue LYS41, 
which was identified to be dominant for the binding by the mutagenesis experiment [9] 
but not observed in docking analysis, formed the high stable 2nd H-bond with GLU102 
on 10B12. The key residue LYS59 involved in three H-bonds (the 8th, the 10th and the 
15th bonds), explaining why its mutation seriously impaired the binding between GPVI 
and 10B12 [7]. Out of expect, ARG166 formed three H-bonds (the 5th, 7th and 16th 
bonds) with GLU102 but it was proved dispensable for the binding by the experiment [9], 
possibly coming from that this mutation might enhance the interactions of GLU102 to 
its two other partners LYS41 and SER44 on GPVI (Table 3). Taken together, two critical 
Table 3 Summary of  survival ratios, rupture time and  involved residues of  hydrogen 
bonds detected from free and steered MD simulations
The heading I and II denote two different equilibrated complex conformation of 10B12 bound to GPVI, and the values 
(Column 8 and 11) of express the thermal and mechanical stabilities of the bonds detected from free and steered MD 
simulations thrice with two different equilibrated conformations (see “Methods” section). The superscript numbers on 
residues (Column 2 and 4) designate the positions of their respective involved residues in sequences of GPVI and 10b12 
with serial numbering, the donor- and acceptor-atoms (Column 5) on paratope residues (Column 4) together with their 
respectively partners (Column 3) on epitope residues (Column 2) contribute to bonds in binding site. All bonds, which were 
derived from thrice independent free and steered MD simulations with equilibrated conformation I and II, respectively, were 
designated by nonzero values (mean ± SD) of survival ratios and rupture times of bonds
Bond GPVI 10B12 Survival ratio Rupture time
No. Residue Atom Residue Atom I II ω I (ns) II (ns) α
1 ARG46 NH2 ASP98 OD1 0.39 ± 0.04 0.94 ± 0.01 0.94 1.20 ± 0.31 2.18 ± 0.81 0.75
2 LYS41 NZ GLU102 OE2 0.79 ± 0.08 0.79 2.88 ± 1.08 0.14 ± 0.11 1.00
3 ARG38 NH2 GLU1 OE1 0.42 ± 0.30 0.66 ± 0.14 0.66 0.69 ± 0.80 1.71 ± 0.50 0.59
4 TYR47 OH GLU1 OE2 0.09 ± 0.04 0.65 ± 0.15 0.65 1.48 ± 0.23 0.51
5 ARG166 NH2 GLU102 OE1 0.56 ± 0.04 0.56 0.44 ± 0.23 0.15
6 ARG46 NH2 ASP111 OD2 0.54 ± 0.29 0.54 2.41 ± 0.71 0.83
7 ARG166 NH1 GLU102 OE2 0.54 ± 0.06 0.54 0.36 ± 0.29 0.12
8 LYS59 NZ ASP107 OD2 0.53 ± 0.27 0.53 0.44 ± 0.25 0.15
9 ARG46 NH1 ASP98 OD1 0.50 ± 0.13 0.50 2.48 ± 0.53 0.86
10 LYS59 NZ ASP108 OD1 0.33 ± 0.10 0.48 ± 0.38 0.48 0.56 ± 0.30 0.30 ± 0.27 0.19
11 SER44 OG GLU102 OE2 0.45 ± 0.11 0.45 1.28 ± 0.98 0.05 ± 0.09 0.44
12 ARG38 NH1 GLU1 OE2 0.44 ± 0.21 0.45 ± 0.09 0.45 0.72 ± 0.80 1.50 ± 0.49 0.52
13 ARG46 NE GLU102 OE1 0.40 ± 0.08 0.40 1.54 ± 0.10 0.02 ± 0.04 0.53
14 SER44 OG GLU102 OE1 0.40 ± 0.10 0.40 1.52 ± 0.35 0.01 ± 0.01 0.53
15 LYS59 NZ ASP108 OD2 0.39 ± 0.08 0.36 ± 0.40 0.39 0.44 ± 0.31 0.15
16 ARG166 NH2 GLU102 OE2 0.30 ± 0.01 0.30 0.61 ± 0.24 0.21
17 LYS59 NZ ASP107 OD1 0.29 ± 0.30 0.29
18 ARG46 NH2 ASP98 OD2 0.27 ± 0.03 . 0.27 1.18 ± 0.92 0.41
19 ARG38 NH2 GLU1 OE2 0.25 ± 0.17 0.21 ± 0.16 0.25 0.56 ± 0.71 0.07 ± 0.07 0.19
20 ARG166 NH1 GLU102 OE1 0.23 ± 0.02 0.23 0.63 ± 0.27 0.22
21 ARG46 NH1 ASP111 OD2 0.23 ± 0.13 0.23 0.71 ± 0.35 0.24
22 SER43 OG GLU102 OE1 0.22 ± 0.20 0.22
23 TYR32 OH ASP167 OD2 0.17 ± 0.35 0.17
24 ARG38 NH1 GLU1 OE1 0.11 ± 0.08 0.12 ± 0.10 0.12 0.57 ± 0.71 0.20
25 TYR47 OH GLU1 OE1 0.01 ± 0.01 0.09 ± 0.12 0.09 0.09 ± 0.08 0.03
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residues on GPVI (LYS41 and LYS59) were both sorted out by H-bonds with moderate 
and high thermal stabilization and the simulations also predicted ten potential key resi-
dues without mutagenesis experiments data.
Mechanical H‑bonding stabilization is another mark for key interaction residues 
across 10B12/GPVI complex interface
Similar to the thermal stabilization reflected by the survival ratios of H-bonds, the 
mechanical stabilizations of H-bonds was also used to map paratope and epitope resi-
dues [21]. Rupture times of all H-bonds (Table 3) were detected from steered MD simu-
lations which were performed thrice for each of the equilibrated conformation I and II 
(see “Methods” section). The random feature and initial-state dependence of H-bonds 
were also observed, similar to those in the free MD simulations. For example, the 5th–
8th bonds only appeared in the simulations for the equilibrated conformation II, while 
and 9th bond emerged only in the simulations for the equilibrated conformation I 
(Table 3). Normalized mean rupture time (α) of each H-bond was calculated and listed 
in Table 3 (see “Methods” section). Seven H-bonds, including 1–4th, 6th, 9th, 11–14th 
and 18th bonds, had high mechanical stabilization for their normalized mean rupture 
time α larger than 0.3. With these H-bonds, nine residues were predicted to be paratope 
and epitope residues, including five (ARG38, LYS41, SER44, ARG46, TYR47) on GPVI and 
four (GLU1, ASP98, GLU102, ASP111) on 10B12 (Table 3; Fig. 3).
A bonding may be stable thermally rather than mechanically and vice versa. It was 
shown from Table 3 that, the 5th, the 7th and the 8th bonds had higher thermal stabi-
lizations for their survival ratio larger than 0.5, but their mechanical stabilizations were 
low because of the normalized mean rupture time α smaller than 0.2; the 18th bond 
was stable mechanically rather than thermally for its mean survival ratio of 0.27 and its 
normalized mean rupture time α of 0.41. Of the above nine residues proposed through 
mechanical stabilization, LYS41 had been identified as an epitope residue by mutagenesis 
experiments, and others had not. In comparison with key residues from free MD simula-
tions, four residues (LYS59, ARG166 on GPVI and ASP107, ASP108 on 10B12) were missed 
Fig. 3 The predicted interaction residues on interface of GPVI-10B12. a The key residues on GPVI and b the 
key residues on 10B12. Red stands for the identified residues via mutagenesis experiments, and blue stands 
for the key residues which were predicted by MD simulation without mutagenesis data, cyan stands for the 
dispensable residues demonstrated by mutation data. All interaction residues on interface of GPVI-10B12 
complex were predicted here by mean survival ratio, normalized mean rupture time or HBSI index
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in the steered MD simulations, where mutation data demonstrated LYS59 dominant and 
ARG166 dispensable for binding [9].
Mapping paratope to epitope via H‑bond stabilization index
To score synthetically the thermal and mechanical stabilization of a hydrogen bonding, 
hydrogen bond stabilization index (HBSI), which was presented in our previous work for 
antithrombotic antibody 6B4 [21], were calculated by the average of the mean survival 
ratio and the normalized mean rupture time of each of all detected bond (see “Methods” 
section). All H-bonds were clustered into three groups with low, moderate and high sta-
bilization by HBSI values ranging from 0 to 0.3, 0.3 to 0.55 and 0.55 to 1.0, respectively.
The H-bonds with HBSI values (from 0.33 to 0.89) ranked in top 15 were predicted to 
be stable (Table 4). Thirteen residues, seven (ARG38, LYS41, SER44, ARG46, TYR47, LYS59, 
and ARG166) on GPVI and six (GLU1, ASP98, GLU102, ASP107, ASP108, ASP111) on 10B12 
and two pre-identified epitope residues (LYS41 and LYS59), were involved in above stable 
bonds. Of these predicted key residue, LYS41 and LYS59 are the identified epitope resi-
dues (Fig. 3) [7, 9]. The key residues from HBSI analysis were the same as those from free 
MD simulations, but the stabilization ranking of their involved H-bonds were different. 
The bond ranked 2nd in survival ratio but 1st in the normalized mean rupture time due 
to the highest mechanical stabilization (Table 4), highlighting the importance of epitope 
residue LYS41; and, the 18th bond was missed from free MD simulations but ranked 14th 
in HBSI, benefiting from its high mechanical stabilization too. It indicated that, mechan-
ical stabilization of bonding should be important in predicting paratope–epitope inter-
actions via MD simulation, and HBSI might include more detailed information about 
paratope–epitope interactions in comparison with survival ratio and rupture time.
Table 4 The stable H-bonds with HBSI values >0.3
a The bond no in column 2 were same as those in Table 3
Rank Bond no.a HBSI Interaction residue pairs
GPVI 10B12
1 2 0.89 LYS41 GLU102
2 1 0.85 ARG46 ASP98
3 6 0.69 ARG46 ASP111
4 9 0.68 ARG46 ASP98
5 3 0.63 ARG38 GLU1
6 4 0.58 TYR47 GLU1
7 12 0.48 ARG38 GLU1
8 13 0.47 ARG46 GLU102
9 14 0.46 SER44 GLU102
10 11 0.45 SER44 GLU102
11 5 0.36 ARG166 GLU102
12 8 0.34 LYS59 ASP107
13 10 0.34 LYS59 ASP108
14 18 0.34 ARG46 ASP98
15 7 0.33 ARG166 GLU102
Page 656 of 658Liu et al. BioMed Eng OnLine 2016, 15(Suppl 2):152
Discussion
Mapping paratope to epitope residues of potent antithrombotic antibody 10B12 is an 
essential step to re-design this antibody for higher affinity or other desired modifica-
tions. However, only two epitope residues without their paratope residues were iden-
tified through mutation experiments [7, 9]. With a novel computational procedure 
proposed in our previous work for the antithrombotic antibody 6B4 [21], we here inves-
tigated the paratope and epitope residues of 10B12/GPVI complex. Successfully, the two 
known identified epitope residues (LYS41 and LYS59) on GPVI were predicted as critical 
residues, and seven residues (ARG60, PHE91, ARG117, TYR118, PHE120, ARG139, SER164 
and ARG166), being dispensable for the binding [7], did not listed in the key interaction 
residues through our computational procedure. These results suggested that our compu-
tational procedure had higher sensitivity and specificity in mapping paratope to epitope 
of the 10B12/GPVI complex. And, other newly predicted ten residues, four (ARG38, 
SER44, ARG46, and TYR47) on GPVI and six (GLU1, ASP98, GLU102, ASP107, ASP108 and 
ASP111) on 10B12, might be important for binding. The reason for this success lies in 
that MD simulations can mimic the atom fluctuations and conformational changes of 
biomolecules in liquid or physiological environment [32, 33].
As illustrated in our previous work for the antithrombotic antibody 6B4 [21], the 
present results indicated again that as a solid linker between a paratope residue and its 
partner, the strong hydrogen bonding across complex interface was a better mark in 
mapping paratope to epitope; the key and abundant messages of paratope and epitope 
residues could be extracted from MD simulation rather than docking analysis, because 
MD simulation would build up a quasi-complete complex conformation space, from 
which most of hydrogen bonding could be detected; the weak thermal disturbing did 
not cross the barrier of conformational transform but mechanical stretch did, this was 
why some key interaction residues had not emerged from free MD simulation but could 
be detected from steered MD simulation; and in the present computer strategy, three 
different complex structures on equilibrium state, at least, should be used to the subse-
quent MD simulation, because of that, the simulated evolution of complex conformation 
was dependent on the initial structure of the complex.
However, it should be noted that the residue ARG166 on GPVI was a false positive in 
our study. Maybe, the reason might come from that the simulation times were not long 
enough and the sampling spaces were not large enough. It remains a room for improve-
ment in the accuracy of the procedure such as through extending the simulation time or 
selecting more initial conformations.
Conclusions
The present computer strategy, combining homology modeling, rigid body docking and 
MD simulation, should be effective not only in mapping paratope on antithrombotic 
antibody 10B12 to epitope on GPVI but also in other antibody researches, have large 
potential in drug discovery and antibody research, provide useful clues to mutation 
experiments and assist the computer-aided antibody design.
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